Bank Of New York Mellon Corp Silverback Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	N/A	15,185 New	15,185 $98.9 Million
Q4 2022 Feb 14, 2023	BUY	$0.0 - $6.07 $0 - $92,172	15,185 New	15,185 $0
Q2 2022 Aug 15, 2022	SELL	$2.9 - $4.44 $170,067 - $260,379	-58,644 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$3.51 - $6.74 $4,973 - $9,550	-1,417 Reduced 2.36%	58,644 $206,000
Q4 2021 Feb 11, 2022	BUY	$6.03 - $11.67 $20,459 - $39,596	3,393 Added 5.99%	60,061 $400,000
Q3 2021 Nov 12, 2021	BUY	$9.98 - $35.22 $170,897 - $603,107	17,124 Added 43.3%	56,668 $566,000
Q2 2021 Aug 11, 2021	BUY	$24.71 - $44.28 $116,927 - $209,532	4,732 Added 13.59%	39,544 $1.22 Million
Q1 2021 May 13, 2021	BUY	$37.62 - $60.41 $1.31 Million - $2.1 Million	34,812 New	34,812 $1.52 Million

163

62.7M

872K

589K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.